GenPath logo in conjunction with oncology

OnkoSightTM Exon Coverage

OnkoSightTM panels are targeted assays that are meant to be highly actionable and reduce the number of unclear variant results. To that end, coverage of the genes included on OnkoSightTM panels has been carefully selected, based on the actionable mutations recommended in established national guidelines and published literature.

ONKOSIGHTTM MYELOID DISORDER PANEL

GENEEXON COVERED
ABL14, 5, 6
ASXL112
BCOR2-15
BCORL11-12
BRAF15
CALR9
CBL8, 9
CDKN2A1, 2
CSF3R14-17
DNMT3A2-23
ETV61-8
EZH22-20
FBXW79-11
FLT313-15, 20
GATA22-4, 6
HRAS2, 3
IDH14
IDH24
JAK212, 14
KIT2, 8-11, 13, 17
KRAS2, 3
MPL10
MYD883-5
NPM111
NRAS2, 3
PHF62-10
PTEN5, 7
PTPN113, 13
RUNX12-9
SETBP14
SF3B113-16
SRSF21
TET23-11
TP532-11
U2AF12, 6
WT17, 9
ZRSR21-11

ONKOSIGHTTM SOLID TUMOR PANEL

GENEEXON COVERED
AKT13
ALK20, 22-25
BRAF11, 15
CTNNB13
DDR25, 8, 13, 15, 17
EGFR7, 12, 15, 18-21
EPHA25
ERBB219-21
ESR17, 9, 10
FGFR15, 8
FGFR27, 9, 12
FGFR37, 9, 14, 18
GNA115
GNAQ5
HRAS2, 3
IDH14
IDH24
KIT9, 11, 13, 14, 17, 18
KRAS2, 3, 4
MAP2K12, 3, 6
MET2, 14, 16, 19
MTOR44, 53
NOTCH126
NRAS2, 3, 4
PDGFRA12, 14, 15, 18
PIK3CA2, 3, 6, 10, 21
PTEN2-9
RAC12
RET10, 11, 13, 15, 16
ROS138
TP532, 4-11

Next-generation sequencing provides increased gene coverage compared to other testing methods, such as PCR. OnkoSightTM panels include the latest actionable biomarkers, improving coverage across genes like EGFR, KRAS, and NRAS.

Onkosight CoverageTM
EGFR:EXON 12EXON 15EXON 18EXON 19EXON 20EXON 21
Targeted PCR Coverage